top of page
  • David Drew, PhD

Now in Science Advances

Dr. Drew along with the Genetics and Epidemiology of Colorectal Cancer Consortium (GECCO) Investigator team has published the findings of the largest Genome Wide Interaction Scan (GWIS) for aspirin and non-steroidal anti-inflammatory drugs (NSAIDs) and genetic modifiers of protective effects against colorectal cancer (CRC). In brief, we found that regular, long-term aspirin use may act synergistically with genetic variants, particularly those in mechanistically relevant pathways, to confer a protective effect on CRC risk.

We leveraged pooled data from more than 50 studies that included more than 30,000 CRC cases and nearly 42,000 controls to identify statistically significant interactions between regular aspirin/NSAID use and a variant in 6q24.1 (rs72833769), which has evidence of influencing expression of a key regulator of MTOR activity, and variants in 5p13.1 (rs350047), that predicts expression of PTGER4 (which encodes a cell surface receptor for PGE2, which is inhibited by aspirin).

1 view0 comments

Bình luận

Post: Blog2_Post
bottom of page